Volume 8, Issue 2 pp. 89-91
CASE REPORT

Sjögren syndrome combined with myositis which is pathologically compatible with inclusion body myositis

Akihiko Mitsutake

Corresponding Author

Akihiko Mitsutake

Department of Neurology, Tokyo Teishin Hospital, Tokyo, Japan

Correspondence

Akihiko Mitsutake, Department of Neurology, Tokyo Teishin Hospital, 2-14-23 Fujimi, Chiyoda-ku, Tokyo 102-8798, Japan.

Email: [email protected]

Search for more papers by this author
Akira Arakawa

Akira Arakawa

Department of Neurology, Tokyo Teishin Hospital, Tokyo, Japan

Search for more papers by this author
Tatsuya Sato

Tatsuya Sato

Department of Neurology, Tokyo Teishin Hospital, Tokyo, Japan

Search for more papers by this author
Junko Katsumata

Junko Katsumata

Department of Neurology, Tokyo Teishin Hospital, Tokyo, Japan

Search for more papers by this author
Tomonari Seki

Tomonari Seki

Department of Neurology, Tokyo Teishin Hospital, Tokyo, Japan

Search for more papers by this author
Risa Maekawa

Risa Maekawa

Department of Neurology, Tokyo Teishin Hospital, Tokyo, Japan

Search for more papers by this author
Takuto Hideyama

Takuto Hideyama

Department of Neurology, Tokyo Teishin Hospital, Tokyo, Japan

Search for more papers by this author
Ichizo Nishino

Ichizo Nishino

Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan

Search for more papers by this author
Yasushi Shiio

Yasushi Shiio

Department of Neurology, Tokyo Teishin Hospital, Tokyo, Japan

Search for more papers by this author
First published: 07 December 2019

Abstract

A 60-year-old woman previously diagnosed as Sjögren syndrome (SjS) presented with a three-year history of progressive muscle weakness in the neck and predominantly proximal part of the four limbs. Pathological study showed patchy, dot-like p62 aggregates in muscle fibers in combination with increased HLA-ABC and -DR expression, which is pathologically consistent with sporadic inclusion body myositis (sIBM). Oral prednisolone improved muscle strength. Three years after the initiation of treatment, the patient still can walk. Myositis in our patient, albeit pathologically characterized by features of sIBM, responded well to prednisolone.

CONFLICT OF INTEREST

The authors disclose no conflicts of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.